The IKKgamma antibody is a crucial tool for studying the IKK (IkB kinase) complex, specifically targeting the regulatory subunit IKKgamma (also known as NEMO or NF-kappa-B essential modulator). IKKgamma is a 48 kDa protein encoded by the IKBKG gene and serves as a scaffold for the IKK complex, which includes catalytic subunits IKKalpha and IKKbeta. This complex plays a central role in activating the NF-κB signaling pathway, a critical regulator of immune responses, inflammation, apoptosis, and cell survival.
IKKgamma facilitates the phosphorylation of IkB proteins by IKKbeta, leading to IkB degradation and subsequent nuclear translocation of NF-κB. Mutations in IKBKG are linked to severe genetic disorders like incontinentia pigmenti and ectodermal dysplasia. Dysregulated NF-κB signaling is also implicated in cancers, autoimmune diseases, and chronic inflammation.
Antibodies against IKKgamma enable researchers to detect protein expression, monitor post-translational modifications (e.g., ubiquitination), and investigate interactions within the IKK complex via techniques like Western blot, immunoprecipitation, and immunofluorescence. They are vital for studying NF-κB activation mechanisms, disease models, and therapeutic targets. Commercial IKKgamma antibodies are typically raised in rabbits or mice, with validation in specific applications. Researchers must verify antibody specificity due to potential cross-reactivity with homologous domains or splice variants.